Cara Therapeutics (CARA) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. TSLA
9. GOOGL
10. CRWV

Go back to Cara Therapeutics (CARA) Tops Q3 EPS by 8c

Cara Therapeutics Reports Third Quarter 2015 Financial Results

November 9, 2015 4:01 PM EST

Initiated Phase 3 program for I.V. CR845 in acute postoperative pain

Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients

Earned $2.75M in milestone payments for clinical development of uremic pruritus

Conference call today at 4:30 p.m. ET

SHELTON, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the third... More